Artisan Pharma, a Waltham, MA-based developer of a biotech drug for a blood-clotting condition in sepsis patients, has raised $9.4 million of an $11.8 million round of debt financing, the firm reported yesterday in an SEC filing. The filing did not specify the investors in the debt round, which may also include the sale of warrants and options to buy equity in Artisan. Artisan says its lead drug, recombinant thrombomodulin, was licensed from Tokyo-based Asahi Kasei Pharma to develop the treatment in non-Asian markets.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
